Why shedding may happen, what the research says, and how to support healthier hair growth
Estimated reading time: 5–6 minutes
You have been working toward your health goals, making changes, and finally seeing progress. Then something unexpected happens.
You notice more hair in the shower. Your ponytail feels smaller, your part looks wider, or your hairbrush seems to collect more strands than usual.
If this sounds familiar, you are not alone.
As GLP-1-based medications such as Ozempic®, Wegovy®, and Zepbound® have become more widely used, more patients have started asking:
“Why am I losing hair when I’m trying to improve my health?”
The answer may involve how the body responds to weight loss, reduced food intake, nutritional changes, medication effects, or a combination of factors.
Important: Do not stop, reduce, or otherwise change a prescription medication without first speaking with the clinician who prescribed it.
Understanding the Hair-Growth Cycle
Hair naturally moves through several phases:
- Anagen: the active growth phase
- Catagen: a short transitional phase
- Telogen: the resting phase
- Exogen: the shedding phase
When the body experiences significant physical or emotional stress, more follicles than usual may enter the resting phase at approximately the same time.
This can lead to telogen effluvium, a form of diffuse hair shedding that may occur after:
- Rapid or substantial weight loss
- Illness or high fever
- Surgery
- Childbirth
- Significant emotional stress
- Restrictive eating
- Nutritional deficiencies
- Certain medications
The shedding often does not begin immediately. It may become noticeable several weeks or months after the triggering event, which can make the cause difficult to recognize.
Telogen effluvium is often temporary, but recovery depends on whether the underlying trigger has been identified and addressed.
Do GLP-1 Medications Directly Cause Hair Loss?
GLP-1-based medications—including semaglutide and tirzepatide—can help regulate appetite, blood sugar, and weight.
Hair loss has been reported among some patients using these medications. However, an association does not necessarily prove that the medication directly damages hair follicles.
Possible contributing factors include:
- Rapid weight loss
- Reduced calorie or protein intake
- Changes in iron, zinc, vitamin D, or other nutrient levels
- Physiological stress associated with weight change
- Hormonal or metabolic shifts
- Unmasking of underlying pattern hair loss
- A direct medication-related effect that has not yet been fully established
Current research has not definitively determined how much each factor contributes.
What Did the Zepbound Clinical Trials Report?
In pooled weight-management trials included in the FDA prescribing information for Zepbound, hair loss was reported in:
- 5% of participants receiving 5 mg
- 4% receiving 10 mg
- 5% receiving 15 mg
- 1% receiving placebo
The prescribing information states that reported hair-loss reactions were associated with weight reduction.
Hair loss was also reported more frequently among female participants. In the pooled trials, it occurred in 7.1% of Zepbound-treated women compared with 1.3% receiving placebo. Among men, the corresponding rates were 0.5% and 0%.
Clinical-trial rates may not predict an individual patient’s experience and should not be directly compared with rates from different medications or studies.
Review the FDA prescribing information
What Does the Broader Research Show?
A 2026 systematic review evaluated 24 studies involving GLP-1 therapies and hair loss.
Semaglutide and tirzepatide had the strongest hair-loss signals among the medications evaluated. Telogen effluvium and androgenetic alopecia were the most frequently identified forms of hair loss when a subtype was reported.
Rapid weight loss was identified as a possible contributor, particularly for telogen effluvium. However, the researchers emphasized that larger prospective studies are needed to determine causality and clarify the relationship between medication, weight loss, nutrition, and hair changes.
Review the 2026 systematic review
Another 2026 systematic review and meta-analysis found an association between GLP-1 receptor agonist use and nonscarring hair loss, including telogen effluvium and androgenetic alopecia. However, much of the available evidence came from observational studies and pharmacovigilance databases, which can identify safety signals but cannot independently establish direct causation.
Review the 2026 meta-analysis
Overall, the evidence suggests a possible association, but it does not yet prove that GLP-1 medications directly injure hair follicles.
Why Nutrition Matters During Weight Loss
When appetite decreases, food intake often decreases as well.
Eating less may support weight loss, but it can also make it more difficult to consume enough nutrients needed for normal hair production.
Protein
Hair is primarily composed of keratin, a protein. Inadequate protein intake may contribute to increased shedding, particularly during rapid weight loss or restrictive eating.
Iron
Low iron stores may be associated with certain forms of hair loss. Testing and treatment should be individualized rather than based on symptoms alone.
Zinc
Zinc plays a role in normal follicle function. Both deficiency and excessive supplementation can cause problems.
Vitamin D
Low vitamin D levels have been associated with some hair-loss conditions, but supplementation does not reliably improve hair growth when a deficiency is not present.
This does not mean everyone taking a GLP-1 medication needs multiple supplements. Unnecessary supplementation can be ineffective or harmful.
A better approach is to maintain balanced nutrition and discuss appropriate laboratory evaluation with a qualified healthcare professional when indicated.
Will the Hair Grow Back?
For many people with telogen effluvium, shedding gradually improves once the underlying trigger is corrected or stabilized.
Visible fullness takes longer to return because hair grows slowly. Even after excessive shedding begins to settle, it may take several additional months for shorter regrowing hairs to contribute noticeable volume.
Recovery timelines vary, and not every case of hair loss after weight loss is telogen effluvium.
Rapid shedding may also reveal an underlying condition such as androgenetic alopecia, or pattern hair loss. In some patients, more than one type of hair loss may be present simultaneously.
When Should Hair Loss Be Evaluated?
Consider seeking an appropriate medical evaluation when hair loss is:
- Sudden or severe
- Patchy rather than diffuse
- Continuing or worsening
- Associated with scalp pain, itching, inflammation, scaling, or scarring
- Accompanied by fatigue, menstrual changes, or other symptoms
- Producing a progressively widening part or receding hairline
- Occurring with a new medication or major health change
An evaluation may include a review of medical history, medications, nutrition, weight-loss rate, scalp condition, hair-loss pattern, and laboratory testing when clinically appropriate.
What Can You Do to Support Your Hair?
Prioritize adequate nutrition
Work with your prescribing clinician or a qualified nutrition professional to maintain adequate protein, calories, and essential nutrients during weight loss.
Avoid self-prescribing supplements
Testing may help determine whether supplementation is appropriate. More is not always better.
Discuss the pace of weight loss
Your prescribing clinician can help determine whether your weight-loss plan and medication schedule remain appropriate for your health needs.
Be gentle with your hair
When shedding is increased:
- Minimize high-heat styling
- Avoid tight hairstyles
- Reduce harsh chemical processing
- Detangle gently
- Avoid repeatedly pulling or testing shedding hairs
Give the process time
Hair growth is slow. Even when the trigger has been addressed, visible recovery does not happen overnight.
Can Hair-Restoration Treatments Help?
Addressing the underlying cause is the first priority.
Additional treatments may be considered when pattern hair loss is also present or when a qualified provider determines that another intervention may be appropriate.
At Infinite Wellness Med Spa, available options may include:
Fotona HairRestart
Fotona HairRestart is a noninvasive laser treatment that delivers controlled thermal energy to the scalp. Early studies suggest potential benefits for certain forms of androgenetic alopecia.
It has not been established as an effective treatment specifically for GLP-1-associated telogen effluvium.
SELPHYL® Platelet-Rich Fibrin Matrix
SELPHYL PRFM is prepared from a sample of the patient’s own blood using a closed preparation system. The resulting platelet-rich fibrin matrix is injected into selected areas of the scalp.
Research involving platelet-based treatments has reported promising findings for androgenetic alopecia, but evidence specific to SELPHYL PRFM remains limited.
Injecting SELPHYL PRFM for hair restoration is an off-label use, and it has not been established as a treatment for GLP-1-associated telogen effluvium.
REVIAN RED®
REVIAN RED is an at-home light-based system designed to support hair growth with consistent use. Light-based therapies have demonstrated benefits in some studies involving pattern hair loss.
Its effectiveness for temporary weight-loss-related shedding or GLP-1-associated telogen effluvium has not been established.
The Right Treatment Begins With the Right Diagnosis
Hair loss after weight loss can feel discouraging, especially when you are making positive changes for your health.
The encouraging news is that many cases of weight-loss-related telogen effluvium may improve after the underlying trigger stabilizes. But because several types of hair loss can look similar, it is important to understand what is happening before choosing a treatment.
At Infinite Wellness Med Spa, we believe hair restoration should begin with education, individualized evaluation, and realistic expectations.
The goal is not simply to treat shedding. It is to understand the possible cause and help you explore an appropriate path forward.
Interested in Learning More?
Schedule a personalized hair-restoration consultation at Infinite Wellness Med Spa in Pasadena, California, to discuss your concerns and learn which options may be appropriate for you.
Medical, Medication and Results Disclaimer
This article is provided for general educational and informational purposes only. It is not medical advice and should not be used to diagnose or treat hair loss, nutritional deficiencies, obesity, diabetes, or any other medical condition.
Do not begin, discontinue, reduce, increase, or otherwise change a prescription medication—including a GLP-1-based medication—without consulting the prescribing clinician.
Hair loss may result from multiple medical, nutritional, hormonal, genetic, inflammatory, and medication-related factors. An in-person evaluation may be necessary to determine the likely cause.
Individual experiences and treatment results vary. No treatment can guarantee reduced shedding, hair regrowth, increased density, or a particular recovery timeline.
Fotona HairRestart, SELPHYL PRFM, and REVIAN RED have not been established as effective treatments specifically for GLP-1-associated telogen effluvium. Their suitability depends on the underlying diagnosis and an individualized assessment.
SELPHYL PRFM scalp injections for hair restoration are an off-label use. All procedures and devices have potential risks, limitations, contraindications, and regulatory considerations that should be discussed before treatment.
Product and medication names are trademarks of their respective owners. Mention of a medication, product, study, or procedure does not constitute an endorsement or a representation that it is appropriate for every patient.
References
- Gupta AK, et al. “GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling.” Science Progress. 2026;109(2). PubMed
- Branyiczky MK, et al. “Effects of GLP-1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review.” International Journal of Dermatology. 2026;65(5):1030–1032. Full article
- Viquez Burboa GU, et al. “GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-Analysis of Incidence, Risk, Subtypes, and Mechanisms.” Skin Appendage Disorders. 2026. PubMed
- Eli Lilly and Company. Zepbound (tirzepatide) Prescribing Information. Hair Loss Adverse Reactions. FDA prescribing information
